Cookie Hinweis

Wir verwenden Cookies, um Ihnen ein optimales Webseiten-Erlebnis zu bieten. Dazu zählen Cookies, die für den Betrieb der Seite notwendig sind, sowie solche, die lediglich zu anonymen Statistikzwecken, für Komforteinstellungen oder zur Anzeige personalisierter Inhalte genutzt werden. Sie können selbst entscheiden, welche Kategorien Sie zulassen möchten. Bitte beachten Sie, dass auf Basis Ihrer Einstellungen womöglich nicht mehr alle Funktionalitäten der Seite zur Verfügung stehen. Weitere Informationen finden Sie in unseren Datenschutzhinweisen .

Essentiell

Diese Cookies sind für die Funktionalität unserer Website erforderlich und können nicht deaktiviert werden.

Name Webedition CMS
Zweck Dieses Cookie wird vom CMS (Content Management System) Webedition für die unverwechselbare Identifizierung eines Anwenders gesetzt. Es bietet dem Anwender bessere Bedienerführung, z.B. Speicherung von Sucheinstellungen oder Formulardaten. Typischerweise wird dieses Cookie beim Schließen des Browsers gelöscht.
Name econda
Zweck Session-Cookie für die Webanalyse Software econda. Diese läuft im Modus „Anonymisiertes Messen“.
Statistik

Diese Cookies helfen uns zu verstehen, wie Besucher mit unserer Webseite interagieren, indem Informationen anonym gesammelt und analysiert werden. Je nach Tool werden ein oder mehrere Cookies des Anbieters gesetzt.

Name econda
Zweck Measure with Visitor Cookie emos_jcvid
Externe Medien

Inhalte von externen Medienplattformen werden standardmäßig blockiert. Wenn Cookies von externen Medien akzeptiert werden, bedarf der Zugriff auf diese Inhalte keiner manuellen Zustimmung mehr.

Name YouTube
Zweck Zeige YouTube Inhalte
Name Twitter
Zweck Twitter Feeds aktivieren

Publikationen

1.  Afshar-Oromieh,A,, Debus,N,, Uhrig,M,, Hope,TA,, Evans,MJ,, Holland-Letz,T,, Giesel,FL,, Kopka,K,, Hadaschik,B,, Kratochwil,C,, Haberkorn,U.: Impact of long-term androgen deprivation therapy on PSMA ligand PET/CT in patients with castration-sensitive prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 45 (12), 2045-2054, 2018.

2.  Anwar,H., Sachpekidis,C., Winkler,J., Kopp-Schneider,A., Haberkorn,U., Hassel,J.C., Dimitrakopoulou-Strauss,A.: Absolute number of new lesions on 18F-FDG PET/CT is more predictive of clinical response than SUV changes in metastatic melanoma patients receiving ipilimumab. European Journal of Nuclear Medicine and Molecular Imaging 45 (3), 376-383, 2018.

3.  Ahmadzadehfar,H., Essler,M., Rahbar,K., Afshar-Oromieh,A.: Radionuclide Therapy for Bone Metastases: Utility of Scintigraphy and PET Imaging for Treatment Planning. PET clinics 13 (4), 491-503, 2018.

4.  Baranski,AC., Schaefer,M., Bauder-Wuest,U., Roscher,M., Schmidt,J., Stenau,E., Simpfendorfer,T., Teber,D., Maier-Hein,L., Hadaschik,B., Haberkorn,U., Ede,M., Kopka,K.: PSMA-11-Derived Dual-Labeled PSMA Inhibitors for Preoperative PET Imaging and Precise Fluorescence-Guided Surgery of Prostate Cancer. Journal of Nuclear Medicine 59 (4), 639-645, 2018.

5.  Blaes ,J.*, Thome,CM*, Pfenning,PN., Rubmann,P., Sahm,F., Wick,A., Bunse,T., Schmenger,T., Sykora,J., von Deimling,A., Wiestler,B., Merz,C., Jugold,M., Haberkorn,U., Abdollahi,A., Debus,J., Gieffers,C., Kunz,C., Bendszus,M., Kluge,M., Platten,M., Fricke,H., Wick,W., Lemke,D., (*=Contributed equally): Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma. Molecular Cancer Research 16 (5), 767-776, 2018.

6.  Buder-Bakhaya,K., Benesova,K., Schulz,C., Anwar,H., Dimitrakopoulou-Strauss,A., Weber,T.F., Enk, A., Lorenz,H.M., Hassel,J.C.: Characterization of arthralgia induced by PD-1 antibody treatment in patients with metastasized cutaneous malignancies. Cancer Immunology Immunotherapy 67 (2), 175-182, 2018.

7.  Debus,C., Afshar-Oromieh,A., Floca,R., Ingrisch,M., Knoll,M., Debus,J., Haberkorn,U., Abdollahi,A.: Feasibility and robustness of dynamic (18)F-FET PET based tracer kinetic models applied to patients with recurrent high-grade glioma prior to carbon ion irradiation. Scientific Reports 8 (1), 14760, 2018.

8.  Debus,C., Waltenberger,M., Floca,R., Afshar-Oromieh,A., Bougatf,N., Adeberg,S., Heiland,S., Bendszus,M., Wick,W., Rieken,S., Haberkorn,U., Debus,J., Knoll,M., Abdollahi,A.: Impact of (18)F-FET PET on Target Volume Definition and Tumor Progression of Recurrent High Grade Glioma Treated with Carbon-Ion Radiotherapy. Scientific Reports 8 (1), 7201, 2018.

9.  Eiber,M., Herrmann,K., Calais,J., Hadaschihk,B., Giesel,FL., Hartenbach,M., Hope,T., Reiter,R., Maurer,T., Weber,WA., Fendler,WP.: PROstate cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET/CT. Journal of Nuclear Medicine 59 (3), 469-478, 2018.

10.  Fanti,S., Minozzi,S., Antoch,G., Banks,I., Briganti,A., Carrio,I., Chiti,A., Clarke,N., Eiber,M., De Bono,J., Fizazi,K., Gillessen,S., Gledhill,S., Haberkorn,U., Herrmann,K., Hicks,RJ., Lecouvet,F., Montironi,R., Ost,P., O'Sullivan,JM., Padhani,AR., Schalken,JA., Scher,HI., Tombal,B., van Moorselaar,RJA., Van Poppel,H., Vargas,HA,, Walz,J., Weber,WA., Wester,HJ., Oyen,WJG.: Consensus on molecular imaging and theranostics in prostate cancer. Lancet Oncology 19 (12), E696-E708, 2018.

11.  Flechsig,P., Walker,C., Kratochwil,C., Konig,L., Iagura,A., Moltz,J., Holland-Letz,T., Kauczor,HU., Haberkorn,U., Giesel,FL.: Role of CT Density in PET/CT-Based Assessment of Lymphoma. Molecular Imaging and Biology 20 (4), 641-649, 2018.

12.  Flechsig,P., Rastgoo,R., Kratochwil,C., Martin,O., Holland-Letz,T., Harms,A., Kauczor,HU., Haberkorn,U., Giesel,FL.: Impact of Computer-Aided CT and PET Analysis on Non-invasive T Staging in Patients with Lung Cancer and Atelectasis. Molecular Imaging and Biology 20 (6), 1044-1052, 2018.

13.  Flechsig,P., Hural,O., Kreuter,M., Eichhorn,M., Heussel,G., Sachpekidis,C., Kauczor,HU., Haberkorn,U., Heussel,CP., Eichinger,M.: Impact of FDG-PET on the Detection of Patients with Lung Cancer at High Risk for ILD. In Vivo 32 (6), 1457-1462, 2018.

14.  Freitag,MT., Kesch,C., Cardinale,J., Flechsig,P., Floca,R., Eiber,M., Bonekamp,D., Radtke,JP., Kratochwil,C., Kopka,K., Hohenfellner,M., Stenzinger,A., Schlemmer,HP., Haberkorn,U., Giesel,F.: Simultaneous whole-body (18)F-PSMA-1007-PET/MRI with integrated high-resolution multiparametric imaging of the prostatic fossa for comprehensive oncological staging of patients with prostate cancer: a pilot study. European Journal of Nuclear Medicine and Molecular Imaging 45 (3), 340-347, 2018.

15.  Giammarile,F., Muylle,K., Bolton,R.D., Kunikowska,J., Haberkorn,U., Oyen,W.: CORRECTION: Dosimetry in clinical radionuclide therapy: the devil is in the detail (vol 44, pg 1, 2017). European Journal of Nuclear Medicine and Molecular Imaging 45 (4), 676-676, 2018.

16.  Giesel,FL., Will,L., Lawal,I., Lengana,T., Kratochwil,C., Vorster,M., Neels,O., Reyneke,F., Haberkorn,U., Kopka,K., Sathekge,M.: Intraindividual Comparison of (18)F-PSMA-1007 and (18)F-DCFPyL PET/CT in the Prospective Evaluation of Patients with Newly Diagnosed Prostate Carcinoma: A Pilot Study. Journal of Nuclear Medicine 59 (7), 1076-1080, 2018.

17.  Giesel,FL., Will,L., Paddubny,K., Kremer,C., Rathke,H., Radtke,JP., Kopka,K., Haufe,S., Haberkorn,U., Kratochwil,C.: [18F]PSMA-1007 PET Improves the Diagnosis of Local Recurrence and Lymph Node Metastases in a Prostate Cancer Patient With a History of Bilateral Hip Arthroplasty. Clinical Genitourinary Cancer 16 (2), 111-113, 2018.

18.  Giesel,FL., Will,L., Kesch,C., Freitag,M., Kremer,C., Merkle,J., Neels,OC., Cardinale,J., Hadaschik,B., Hohenfellner,M., Kopka,K., Haberkorn,U., Kratochwil,C.: Biochemical Recurrence of Prostate Cancer: Initial Results with [(18)F]PSMA-1007 PET/CT. Journal of Nuclear Medicine 59 (4), 632-635, 2018.

19.  Kesch,C., Radtke,J-P., Wintsche,A., Wiesenfarth,M., Luttje,M., Gasch,C., Dieffenbacher,S., Pecqueux,C., Teber,D., Hatiboglu,G., Nyarangi-Dix,J., Simpfendörfer,T., Schönberg,G., Dimitrakopoulou-Strauss,A., Freitag,M., Duensing,A., Grüllich,C., Jäger,D., Götz,M., Grabe,N., Schweiger, M-R., Pahernik,S., Perner,S., Herpel,E., Roth,W., Wieczorek,K., Maier-Hein,K., Debus,J., Haberkorn,U., Giesel,F., Galle,J., Hadaschik,B., Schlemmer,H-P., Hohenfellner,M., Bonekamp,D., Sültmann,H., Duensing,S.: Correlation between genomic index lesions and mpMRI and 68 Ga-PSMA-PET/CT imaging features in primary prostate cancer. Scientific Reports 8 (1), 16708, 2018.

20.  Kratochwil,C., Bruchertseifer,F., Rathke,H., Hohenfellner,M., Giesel,FL., Haberkorn,U., Morgenstern,A.: Targeted alpha-Therapy of Metastatic Castration-Resistant Prostate Cancer with (225)Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. Journal of Nuclear Medicine 59 (5), 795-802, 2018.

21.  Kratochwil,C., Schmidt,K., Afshar-Oromieh,A., Bruchertseifer,F., Rathke,H., Morgenstern,A., Haberkorn,U., Giesel,F.L.: Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617. European Journal of Nuclear Medicine and Molecular Imaging 45 (1), 31-37, 2018.

22.  Larribere,L., Kuphal,S., Sachpekidis,C., Huser,L., Bosserhoff,A., Utikal,J.: Targeted Therapy-Resistant Melanoma Cells Acquire Transcriptomic Similarities with Human Melanoblasts. Cancers 10 (11), 2018. 

23.  Lindner,T., Loktev,A., Altmann,A., Giesel,F., Kratochwil,C., Debus,J., Jäger,D., Mier,W., Haberkorn,U.: Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein. Journal of Nuclear Medicine 59 (9), 1415-1422, 2018.

24.  Loktev,A., Lindner,T., Mier,W., Debus,J., Altmann,A., Jäger,D., Giesel,F., Kratochwil,C., Barthe,P., Roumestand,C., Haberkorn,U.: A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts. Journal of Nuclear Medicine 59 (9), 1423-1429, 2018.

25.  Liolios,C., Buchmuller,B., Bauder-Wuest,U., Schaefer,M., Leotta,K., Haberkorn,U., Eder,M., Kopka,K.: Monomeric and Dimeric (68)Ga-Labeled Bombesin Analogues for Positron Emission Tomography (PET) Imaging of Tumors Expressing Gastrin-Releasing Peptide Receptors (GRPrs). Journal of Medicinal Chemistry 61 (5), 2062-2074, 2018.

26.  Majenka,P., Hoffmann,M., Rötzer,I., Dimitrakopoulou-Strauss,A., Koschny,R., Longerich,T., Enk,A., Hassel,J.C..: Diet-dependent toxicity of ipilimumab in metastatic melanoma. European Journal of Cancer 106, 220-224, 2018.

27.  Mavriopoulou,E., Zampakis,P., Smpiliri,E., Spyridonidis,T., Rapti,E., Haberkorn,U., Makatsoris,T., Apostolopoulos,DJ.: Whole body bone SPET/CT can successfully replace the conventional bone scan in breast cancer patients. A prospective study of 257 patients. Hellenic Journal of Nuclear Medicine 21 (2), 125-133, 2018.

28.  Melzig,C., Fahim Golestaneh,A., Mier,W., Schwager,CD., Das,S., Schlege,J., Lasitschka,F., Kauczor,H.U., Debus,J., Haberkorn,U., Abdollahi,A.: Combined external beam radiotherapy with carbon ions and tumor targeting endoradiotherapy. Oncotarget 9 (52), 29985-30004, 2018.

29. Paddubny,K., Freitag,M.T., Kratochwil,C., Koerber,S., Radtke,J.P., Sakovich,R., Kopka,K., Giesel,F.L.: Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy. Clinical Genitourinary Cancer 16 (2), 103-105, 2018.

30.  Paech,D., Klopries,K., Doll,S., Nawrotzki,R., Schlemmer,HP., Giesel,FL., Kuner,T.: Contrast-enhanced cadaver-specific computed tomography in gross anatomy teaching. European Radiology 28 (7), 2838-2844, 2018.

31.  Rathke,H., Afshar-Oromieh,A., Giesel,FL., Kremer,C., Flechsig,P., Haufe,S., Mier,W., Holland-Letz,T., De Bucourt,M., Armor,T., Babich,JW., Haberkorn,U., Kratochwil,C.: Intraindividual Comparison of (99m)Tc-Methylene Diphosphonate and Prostate-Specific Membrane Antigen Ligand (99m)Tc-MIP-1427 in Patients with Osseous Metastasized Prostate Cancer. Journal of Nuclear Medicine 59 (9), 1373-1379, 2018.

32.  Rathke,H., Giesel,FL., Flechsig,P., Kopka,K., Mier,W., Hohenfellner,M., Haberkorn,U., Kratochwil,C.: Repeated (177)Lu-Labeled PSMA-617 Radioligand Therapy Using Treatment Activities of Up to 9.3 GBq. Journal of Nuclear Medicine 59 (3), 459-465, 2018.

33.  Roesch,S., Lindner,T., Sauter,M., Loktev,A., Flechsig,P., Muller,M., Mier,W., Warta,R., Dyckhoff,G., Herold-Mende,C., Haberkorn,U., Altmann,A.: Comparison of the RGD Motif-Containing alphavbeta6 Integrin-Binding Peptides SFLAP3 and SFITGv6 for Diagnostic Application in HNSCC. Journal of Nuclear Medicine 59 (11), 1679-1685, 2018.

34.  Rohrich,M., Huang,K., Schrimpf,D., Albert,NL., Hielscher,T., von Deimling,A., Schuller,U., Dimitrakopoulou-Strauss,A., Haberkorn,U.: Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas. European Journal of Nuclear Medicine and Molecular Imaging 45 (9), 1573-1584, 2018.

35.  Sachpekidis,C., Anwar,H., Winkler,J., Kopp-Schneider,A., Larribere,L., Haberkorn,U., Hassel,JC., Dimitrakopoulou-Strauss,A.: The role of interim (18)F-FDG PET/CT in prediction of response to ipilimumab treatment in metastatic melanoma. European Journal of Nuclear Medicine and Molecular Imaging 45 (8), 1289-1296, 2018.

36.  Sachpekidis,C., Pan,L., Hadaschik,B.A., Kopka,K., Haberkorn,U., Dimitrakopoulou-Strauss,A.: (68)Ga-PSMA-11 PET/CT in prostate cancer local recurrence: impact of early images and parametric analysis. Journal of Nuclear Medicine 8 (5), 351-359, 2018.

37.  Sachpekidis,C., Anwar,H., Winkler,J.K., Kopp-Schneider,A., Larribere,L., Haberkorn,U., Hassel,J.C., Dimitrakopoulou-Strauss,A.: Longitudinal studies of the F-18-FDG kinetics after ipilimumab treatment in metastatic melanoma patients based on dynamic FDG PET/CT. Cancer Immunology Immunotherapy 67 (8), 1261-1270, 2018.

38.  Sachpekidis,C., Baeumer,P., Kopka,K., Hadaschik,B.A., Hohenfellner,M., Kopp-Schneider,A., Haberkorn,U., Dimitrakopoulou-Strauss,A.: Ga-68-PSMA PET/CT in the evaluation of bone metastases in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 45 (6), 904-912, 2018.

39.  Sachpekidis,C., Goldschmidt,H., Kopka,K., Kopp-Schneider,A., Dimitrakopoulou-Strauss,A.: Assessment of glucose metabolism and cellular proliferation in multiple myeloma: a first report on combined F-18-FDG and F-18-FLT PET/CT imaging. EJNMMI Research 8, 2018.

40.  Sachpekidis,C., Sachpekidis,V., Moralidis,E., Arsos,G.: Equilibrium radionuclide ventriculography: still a clinically useful method for the assessment of cardiac function?. Hellenic Journal of Nuclear Medicine 21 (3), 213-220, 2018. [Version-Id: 92519; Published-Id: 92519; Kst: E060]

41.  Soldatos,TG., Dimitrakopoulou-Strauss,A., Larribere,L., Hassel,JC., Sachpekidis,C.: Retrospective Side Effect Profiling of the Metastatic Melanoma Combination Therapy Ipilimumab-Nivolumab Using Adverse Event Data. Diagnostics 8 (4), 2018.

42.  Taieb,D., Foletti,JM., Bardies,M., Rocchi,P., Hicks,RJ., Haberkorn,U.: PSMA-Targeted Radionuclide Therapy and Salivary Gland Toxicity: Why Does It Matter?. Journal of Nuclear Medicine 59 (5), 747-748, 2018.

43.  Zacho,HD., Nielsen,JB., Dettmann,K., Haberkorn,U., Langkilde,NC., Jensen,JB., Petersen,LJ.: 68Ga-PSMA PET/CT in Patients With Biochemical Recurrence of Prostate Cancer: A Prospective, 2-Center Study. Clinical Nuclear Medicine 43 (8), 579-585, 2018.

44.  Zacho,HD., Nielsen,JB., Afshar-Oromieh,A., Haberkorn,U., deSouza,N., De Paepe,K., Dettmann,K., Langkilde,NC., Haarmark,C., Fisker,RV., Arp,DT., Carl,J., Jensen,JB., Petersen,LJ.: Prospective comparison of (68)Ga-PSMA PET/CT, (18)F-sodium fluoride PET/CT and diffusion weighted-MRI at for the detection of bone metastases in biochemically recurrent prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 45 (11), 1884-1897, 2018.

45.  Zacho,H.D., Nielsen,J.B., Haberkorn,U., Stenholt,L., Petersen,L.J.: 68 Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature. Clinical Physiology and Functional Imaging 38 (6), 911-922, 2018.

 

nach oben
powered by webEdition CMS